Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in Advanced Gynecologic Malignancies
CTR20210400Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in Cervical Cancer (CC), endometrial cancer (EC), Ovarian Epithelial Adenocarcinoma, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Akeso, Inc.. Started Mar 2021; status: completed.
02
Drugs
ivonescimab
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20210400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210400.